Perspectives for a Protective HIV-1 Vaccine

Advances in Pharmacology

Volumn 56, Issue , 2008, Pages 423-452

  Schiavone, Marco ^a   Quinto, Ileana ^a   Scala, Giuseppe ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE;

ANIMAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; REVIEW; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; T-LYMPHOCYTES; VACCINES, ATTENUATED;

EID: 37249062633     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(07)56014-X     Document Type: Review

References (152)

1. Abel K., Compton L., Rourke T., Montefiori D., Lu D., Rothaeusler K., Fritts L., Bost K., and Miller C.J. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J. Virol. 77 (2003) 3099-3118
2. Alter G., Malenfant J.M., Delabre R.M., Burgett N.C., Yu X.G., Lichterfeld M., Zaunders J., and Altfeld M. Increased natural killer cell activity in viremic HIV-1 infection. J. Immunol. 173 8 (2004) 5305-5311
3. Altfeld M., Allen T.M., Yu X.G., Johnston M.N., Agrawal D., Korber B.T., Montefiori D.C., O'Connor D.H., Davis B.T., Lee P.K., Maier E.L., Goulder P.J., et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 420 (2002) 434-439
4. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
5. Amyes E., Hatton C., Montamat-Sicotte D., Gudgeon N., Rickinson A.B., McMichael A.J., and Callan M.F. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med. 198 6 (2003) 903-911
6. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A., Ogg G.S., Spiegel H.M., Conlon C., Spina C.A., Havlir D.V., Richman D.D., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192 1 (2000) 63-75
7. Arthur L.O., Bess Jr. J.W., Chertova E.N., Rossio J.L., Esser M.T., Benveniste R.E., Henderson L.E., and Lifson J.D. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine. AIDS Res. Hum. Retroviruses 14 Suppl. 3 (1998) S311-S319
8. Baba T.W., Jeong Y.S., Pennick D., Bronson R., Greene M.F., and Ruprecht R.M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267 (1995) 1820-1825
9. Baba T.W., Liska V., Khimani A.H., Ray N.B., Dailey P.J., Penninck D., Bronson R., Greene M.F., McClure H.M., Martin L.N., and Ruprecht R.M. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5 (1999) 194-203
10. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., Wang S., Mboudjeka I., Leung L., Lian Y., Fong A., Buckner C., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75 (2001) 5526-5540
11. Bhardwaj N. Processing and presentation of antigens by dendritic cells: Implications for vaccines. Trends Mol. Med. 7 9 (2001) 388-394 (Review)
12. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
13. Birch M.R., Learmont J.C., Dyer W.B., Deacon N.J., Zaunders J.J., Saksena N., Cunningham A.L., Mills J., and Sullivan J.S. An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J. Clin. Virol. 22 (2001) 263-270
14. Boots L.J., McKenna P.M., Arnold B.A., Keller P.M., Gorny M.K., Zolla-Pazner S., Robinson J.E., and Conley A.J. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. AIDS Res. Hum. Retroviruses 13 (1997) 1549-1559
15. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68 9 (1994) 6103-6110
16. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., Nelson J.A., Gairin J.E., Hahn B.H., Oldstone M.B., and Shaw G.M. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3 2 (1997) 205-211
17. Buonaguro L., Racioppi L., Tornesello M.L., Arra C., and Visciano M.L. Induction of neutralizing antibodies and cytotoxic T lymphocytes in BALB/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res. 54 (2002) 189-201
18. Burton D.R. A vaccine for HIV type 1: The antibody perspective. Proc. Natl Acad. Sci. USA 94 (1997) 10018-10023
19. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 (2003) 2065-2071
20. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., and Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 (2005) 163-173
21. Chakrabarti B.K., Ling X., Yang Z.Y., Montefiori D.C., Panet A., Kong W.P., Welcher B., Louder M.K., Mascola J.R., and Nabel G.J. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 23 (2005) 3434-3445
22. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., Appay V., Rizzardi G.P., Fleury S., Lipp M., Forster R., Rowland-Jones S., et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410 6824 (2001) 106-111
23. Chan D.C., and Kim P.S. HIV entry and its inhibition. Cell 93 (1998) 681-684
24. Chen X., Scala G., Quinto I., Liu W., Chun T.W., Justement J.S., Cohen O.J., vanCott T.C., Iwanicki M., Lewis M.G., Greenhouse J., Barry T., et al. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat. Med. 7 (2001) 1225-1231
25. Chen B., Vogan E.M., Gong H., Skehel J.J., Wiley D.C., and Harrison S.C. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433 (2005) 834-841
26. Cho M.W., Kim Y.B., Lee M.K., Gupta K.C., Ross W., Plishka R., Buckler-White A., Igarashi T., Theodore T., Byrum R., Kemp C., Montefiori D.C., et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 75 (2001) 2224-2234
27. Choe H., Li W., Wright P.L., Vasilieva N., Venturi M., Huang C.C., Grundner C., Dorfman T., Zwick M.B., Wang L., Rosenberg E.S., Kwong P.D., et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114 (2003) 161-170
28. Clerici M., Levin J.M., Kessler H.A., Harris A., Berzofsky J.A., Landay A.L., and Shearer G.M. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 271 (1994) 42-46
29. Cortese R., Monaci P., Luzzago A., Santini C., Bartoli F., Cortese I., Fortugno P., Galfre G., Nicosia A., and Felici F. Selection of biologically active peptides by phage display of random peptide libraries. Curr. Opin. Biotechnol. 7 (1996) 616-621
30. Curran J.W., Morgan W.M., Hardy A.M., Jaffe H.W., Darrow W.W., and Dowdle W.R. The epidemiology of AIDS: Current status and future prospects. Science 229 4720 (1985) 1352-1357
31. Dale C.J., Liu X.S., De Rose R., Purcell D.F., Anderson J., Xu Y., Leggatt G.R., Frazer I.H., and Kent S.J. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: Immunogenicity and protective efficacy in macaques. Virology 301 (2002) 176-187
32. Deacon J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., McPhee D.A., Greenway A.L., Ellett A., Chatfield C., Lawson V.A., Crowe S., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270 (1995) 988-991
33. Denesvre C., Le Grand R., Boissin-Cans F., Chakrabarti L., Hurtrel B., Vaslin B., Dormont D., and Sonigo P. Highly attenuated SIVmac142 is immunogenic but does not protect against SIVmac251 challenge. AIDS Res. Hum. Retroviruses 11 (1995) 1397-1406
34. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 5666 (2004) 2019-2022
35. Doan L.X., Li M., Chen C.Y., and Yao Q.Z. Virus-like particles as HIV-1 vaccines. Rev. Med. Virol. 15 (2005) 75-88
36. Dorfman T., Mammano F., Haseltine W.A., and Gottlinger H.G. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 68 3 (1994) 1689-1696
37. Dorner F., and Barrett P.N. Vaccine technology: Looking to the future. Ann. Med. 31 (1999) 51-60
38. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., Grossman Z., Dybul M., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 6884 (2002) 95-98
39. Dyer W.B., Ogg G.S., Demoitie M.A., Jin X., Geczy A.F., Rowland-Jones S.L., McMichael A.J., Nixon D.F., and Sullivan J.S. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J. Virol. 73 (1999) 436-443
40. Edupuganti S., Weber D., and Poole C. Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: A meta-analysis of published studies. HIV Clin. Trials 5 (2004) 259-268
41. Eichberg J.W., Murthy K.K., Ward R.H., and Prince A.M. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG. AIDS Res. Hum. Retroviruses 8 (1992) 1515
42. Emini E.A., Schleif W.A., Nunberg J.H., Conley A.J., Eda Y., Tokiyoshi S., Putney S.D., Matsushita S., Cobb K.E., Jett C.M., Eichberg J.W., Murthy K.K., et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355 (1992) 728-730
43. Enose Y., Kita M., Yamamoto T., Suzuki H., Miyake A., Horiuchi R., Ibuki K., Kaneyasu K., Kuwata T., Takahashi E., Sakai K., Shinohara K., et al. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination. Arch. Virol. 149 (2004) 1705-1720
44. Evans D.T., O'Connor D.H., Jing P., Dzuris J.L., Sidney J., da Silva J., Allen T.M., Horton H., Venham J.E., Rudersdorf R.A., Vogel T., Pauza C.D., et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5 11 (1999) 1270-1276
45. Fonteneau J.F., Larsson M., Beignon A.S., McKenna K., Dasilva I., Amara A., Liu Y.J., Lifson J.D., Littman D.R., and Bhardwaj N. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J. Virol. 78 10 (2004) 5223-5232
46. Fultz P.N., McClure H.M., Swenson R.B., McGrath C.R., Brodie A., Getchell J.P., Jensen F.C., Anderson D.C., Broderson J.R., and Francis D.P. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: A potential model for acquired immunodeficiency syndrome. J. Virol. 58 1 (1986) 116-124
47. Gao F., Korber B.T., Weaver E., Liao H.X., Hahn B.H., and Haynes B.F. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev. Vaccines 3 (2004) S161-S168
48. Gao F., Weaver E.A., Lu Z.J., Li Y.Y., Liao H.X., Ma B., Alam S.M., Scearce R.M., Sutherland L.L., Yu J.-S., Decker J.M., Shaw G.M., et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J. Virol. 79 (2005) 1154-1163
49. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., and Korber B. Diversity considerations in HIV-1 vaccine selection. Science 296 (2002) 2354-2360
50. Gauduin M.C., Parren P.W., Weir R., Barbas C.F., Burton D.R., and Koup R.A. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3 (1997) 1389-1393
51. Gibbs J.S., Regier D.A., and Desrosiers R.C. Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retroviruses 10 (1994) 607-616
52. Girard M., Barre-Sinoussi F., and van der Ryst E. Vaccination of chimpanzees against HIV-1. Antibiot. Chemother. 48 (1996) 121-124
53. Goh W.C., Markee J., Akridge R.E., Meldorf M., Musey L., Karchmer T., Krone M., Collier A., Corey L., Emerman M., and McElrath M.J. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J. Infect. Dis. 179 (1999) 548-557
54. Gotte M., Li X., and Wainberg M.A. HIV-1 reverse transcription: A brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch. Biochem. Biophys. 365 2 (1999) 199-210 (Review)
55. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P., Luzzi G., Morgana B., Edwards A., McMichael A.J., Rowland-Jones S., et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3 (1997) 212-217
56. Grundner C., Mirzabekov T., Sodroski J., and Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 76 (2002) 3511-3521
57. Grundner C., Li Y., Louder M., Mascola J., Yang X., Sodroski J., and Wyatt R. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331 (2005) 33-46
58. Harro C., Edupuganti S., Goepfert P., Priddya F., Lally M., Shiver J., Li X., Robertson M., Leavitt R., and Isaacs R. Safety and immunogenicity of Adenovirus Type 5 (Ad5) HIV-1 gag vaccines. 12th Conf. Retrovir. Oppor. Infect (2005) Abstract 504
59. Haynes B.F., Fleming J., St. Clair W.E., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 (2005) 1906-1908
60. Herrera C., Klasse P.J., Michael E., Kake S., Barnes K., Kibler C.W., and Moore J.P. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 338 (2005) 154-172
61. Hladik F., Desbien A., Lang J., Wang L., Ding Y., Holte S., Wilson A., Xu Y., Moerbe M., Schmechel S., and McElrath M.J. Most highly exposed seronegative men lack HIV-1-specific, IFN-γ-secreting T cells. J. Immunol. 171 (2003) 2671-2683
62. Holmes R.K., Koning F.A., Bishop K.N., and Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282 4 (2007) 2587-2595 Epub 2006 Nov 22
63. Igarashi T., Ami Y., Yamamoto H., Shibata R., Kuwata T., Mukai R., Shinohara K., Komatsu T., Adachi A., and Hayami M. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: A potential candidate live-attenuated human AIDS vaccine. J. Gen. Virol. 78 (1997) 985-989
64. Iida T., Kuwata T., Ui M., Suzuki H., Miura T., Ibuki K., Takahashi H., Yamamoto T., Imanishi J., Hayami M., and Kita M. Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma. Arch. Virol. 149 (2004) 743-757
65. Jekle A., Schramm B., Jayakumar P., Trautner V., Schols D., De Clercq E., Mills J., Crowe S.M., and Goldsmith M.A. Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J. Virol. 76 (2002) 6966-6973
66. Johnson R.P. Mechanisms of protection against simian immunodeficiency virus infection. Vaccine 20 (2002) 1985-1987
67. Johnson R.P., and Desrosiers R.C. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10 (1998) 436-443
68. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., Yang J., Montefiori D.C., Montelaro R., Wyand M.S., and Desrosiers R.C. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation. J. Virol. 73 (1999) 4952-4961
69. Jones T. Hepagene (PowderJect). Curr. Opin. Investig. Drugs 3 (2002) 54-57
70. Jones N.A., Wei X., Flower D.R., Wong M., Michor F., Saag M.S., Hahn B.H., Nowak M.A., Shaw G.M., and Borrow P. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J. Exp. Med. 200 10 (2004) 1243-1256
71. Kang S.M., Quan F.S., Huang C.Z., Guo L.H., Ye L., Yang C., and Compans R.W. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology 331 (2005) 20-32
72. Kaul R., Plummer F.A., Kimani J., Dong T., Kiama P., Rostron T., Njagi E., MacDonald K.S., Bwayo J.J., McMichael A.J., and Rowland-Jones S.L. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164 (2000) 1602-1611
73. Kaul R., Rowland-Jones S.L., Kimani J., Dong T., Yang H.B., Kiama P., Rostron T., Njagi E., Bwayo J.J., MacDonald K.S., McMichael A.J., Plummer F.A., et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J. Clin. Invest. 107 (2001) 341-349
74. Kestler III H.V., Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., and Desrosiers R.C. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65 (1991) 651-662
75. Kim J.H., Pitisuttithum P., Kamboonruang C., Chuenchitra T., Mascola J., Frankel S.S., DeSouza M.S., Polonis V., McLinden R., Sambor A., Brown A.E., Phonrat B., et al. Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: Detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res. Hum. Retroviruses 19 (2003) 807-816
76. Kim Y.B., Han D.P., Cao C., and Cho M.W. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 305 (2003) 124-137
77. Korber B., Muldoon M., Theiler J., Gao F., Gupta R., Lapedes A., Hahn B.H., Wolinsky S., and Bhattacharya T. Timing the ancestor of the HIV-1 pandemic strains. Science 288 (2000) 1789-1796
78. Kumar A., Lifson J.D., Silverstein P.S., Jia F., Sheffer D., Li Z., and Narayan O. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses. Virology 274 (2000) 149-164
79. Kumar A., Mukherjee S., Shen J., Buch S., Li Z., Adany I., Liu Z., Zhuge W., Piatak Jr. M., Lifson J., McClure H., and Narayan O. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Virology 301 (2002) 189-205
80. Kuwata T., Igarashi T., Ido E., Jin M., Mizuno A., Chen J., and Hayami M. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication. J. Gen. Virol. 76 Pt 9 (1995) 2181-2191
81. Kwong P.D. Human immunodeficiency virus: Refolding the envelope. Nature 433 (2005) 815-816
82. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
83. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.-C., Venturi M., Petropoulos C.J., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77 (2003) 10557-10565
84. Learmont J., Tindall B., Evans L., Cunningham A., Cunningham P., Wells J., Penny R., Kaldor A., and Cooper D. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 340 (1992) 863-867
85. Lemiale F., Brand D., Lebigot S., Verrier B., Buzelay L., Brunet S., and Barin F. Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: A comparative study using multivalent vaccine approaches. J. Acquir. Immune Defic. Syndr. 26 (2001) 413-422
86. Lewis J., Balfe P., Arnold C., Kaye S., Tedder R.S., and McKeating J.A. Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J. Virol. 72 (1998) 8943-8951
87. Lifson J.D., Rossio J.L., Piatak Jr. M., Bess Jr. J., Chertova E., Schneider D.K., Coalter V.J., Poore B., Kiser R.F., Imming R.J., Scarzello A.J., Henderson L.E., et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res. Hum. Retroviruses 20 (2004) 772-787
88. Louwagie J., McCutchan F.E., Peeters M., Brennan T.P., Sanders-Buell E., Eddy G.A., van der Groen G., Fransen K., Gershy-Damet G.M., Deleys R., et al. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 7 6 (1993) 769-780
89. Lu S., Wyatt R., Richmond J.F., Mustafa F., Wang S., Weng J., Montefiori D.C., Sodroski J., and Robinson H.L. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retroviruses 14 (1998) 151-155
90. Luciw P.A., Shaw K.E., Shacklett B.L., and Marthas M.L. Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) envelope glycoprotein for pathogenesis. Virology 252 (1998) 9-16
91. MacGregor R.R., Ginsberg R., Ugen K.E., Baine Y., Kang C.U., Tu X.M., Higgins T., Weiner D.B., and Boyer J.D. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS 16 (2002) 2137-2143
92. Mackay G.A., Liu Z., Singh D.K., Smith M.S., Mukherjee S., Sheffer D., Jia F., Adany I., Sun K.H., Dhillon S., Zhuge W., and Narayan O. Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus. J. Immunol. 173 (2004) 4100-4107
93. Marthas L., Sutjipto S., Higgins J., Lohman B., Torten J., Luciw P.A., Marx P.A., and Pedersen N.C. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J. Virol. 64 (1990) 3694-3700
94. Mascola J.R., Louder M.K., VanCott T.C., Sapan C.V., Lambert J.S., Muenz L.R., Bunow B., Birx D.L., and Robb M.L. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71 (1997) 7198-7206
95. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., and Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2000) 207-210
96. Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., and Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434 7037 (2005) 1093-1097
97. McIntyre L.B., Geczy A.F., Dyer W.B., Learmont J.C., and Sullivan J.S. The Sydney Blood Bank Cohort: A case-control study using a transfused HIV-1 seronegative group. Ann. Epidemiol. 9 (1999) 436-440
98. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10 (2004) 1240-1244
99. Miller C.J., and Abel K. Immune mechanisms associated with protection from vaginal SIV challenge in rhesus monkeys infected with virulence-attenuated SHIV 89.6. J. Med. Primatol. 34 (2005) 271-281
100. Montefiori D.C., Baba T.W., Li A., Bilska M., and Ruprecht R.M. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. J. Immunol. 157 (1996) 5528-5535
101. Montefiori D.C., Safrit J.T., Lydy S.L., Barry A.P., Bilska M., Vo H.T., Klein M., Tartaglia J., Robinson H.L., and Rovinski B. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J. Virol. 75 (2001) 5879-5890
102. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X., Binley J.M., Zhang M.-Y., Sidorov I.A., Broder C.C., Robinson J., Parren P.W.H.I., Burton D.R., et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. USA 99 (2002) 6913-6918
103. Mullins J.I., Nickle D.C., Heath L., Rodrigo A.G., and Learn G.H. Immunogen sequence: The fourth tier of AIDS vaccine design. Expert Rev. Vaccines 3 (2004) S151-S159
104. Myers G. Tenth anniversary perspectives on AIDS. HIV: Between past and future. AIDS Res. Hum. Retroviruses 10 11 (1994) 1317-1324 (Review; No abstract available)
105. Nilsson C., Makitalo B., Thorstensson R., Norley S., Binninger-Schinzel D., Cranage M., Rud E., Biberfeld G., and Putkonen P. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12 (1998) 2261-2270
106. Novembre F.J., Saucier M., Anderson D.C., Klumpp S.A., O'Neil S.P., Brown II C.R., Hart C.E., Guenthner P.C., Swenson R.B., and McClure H.M. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type. J. Virol. 71 5 (1997) 4086-4091
107. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., and Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 (2004) 10724-10737
108. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., and Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 17 (2001) 8340-8347
109. Pitcher C.J., Quittner C., Peterson D.M., Connors M., Koup R.A., Maino V.C., and Picker L.J. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5 5 (1999) 518-525
110. Pitisuttithum P., Berman P.W., Phonrat B., Suntharasamai P., Raktham S., Srisuwanvilai L.O., Hirunras K., Kitayaporn D., Kaewkangwal J., Migasena S., Sheppard H.W., Li E., et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J. Acquir. Immune Defic. Syndr. 37 (2004) 1160-1165
111. Poignard P., Moulard M., Golez E., Vivona V., Franti M., Venturini S., Wang M., Parren P.W., and Burton D.R. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77 (2003) 353-365
112. Poon B., Safrit J.T., McClure H., Kitchen C., Hsu J.F., Gudeman V., Petropoulos C., Wrin T., Chen I.S., and Grovit-Ferbas K. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J. Virol. 79 (2005) 4927-4935
113. Price D.A., Goulder P.J., Klenerman P., Sewell A.K., Easterbrook P.J., Troop M., Bangham C.R., and Phillips R.E. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94 5 (1997) 1890-1895
114. Pulendran B., Palucka K., and Banchereau J. Sensing pathogens and tuning immune responses. Science 293 5528 (2001) 253-256 (Review)
115. Quinto I., Puca A., Greenhouse J., Silvera P., Yalley-Ogunro J., Lewis M.G., Palmieri C., Trimboli F., Byrum R., Adelsberger J., Venzon D., Chen X., et al. High attenuation and immunogenicity of a simian immunodeficiency virus expressing a proteolysis-resistant inhibitor of NF-kappaB. J. Biol. Chem. 279 3 (2004) 1720-1728
116. Ratner L., Fisher A., Jagodzinski L.L., Mitsuya H., Liou R.S., Gallo R.C., and Wong-Staal F. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3 1 (1987) 57-69
117. Reitter J.N., Means R.E., and Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4 (1998) 679-684
118. Rhodes D., Solomon A., Bolton W., Wood J., Sullivan J., Learmont J., and Deacon N. Identification of a new recipient in the Sydney Blood Bank Cohort: A long-term HIV type 1-infected seroindeterminate individual. AIDS Res. Hum. Retroviruses 15 (1999) 1433-1439
119. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., Montefiori D., Roberts A., Buonocore L., and Rose J.K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 (2001) 539-549
120. Rossio J.L., Esser M.T., Suryanarayana K., Schneider D.K., Bess Jr. J.W., Vasquez G.M., Wiltrout T.A., Chertova E., Grimes M.K., Sattentau Q., Arthur L.O., Henderson L.E., et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72 (1998) 7992-8001
121. Rowland-Jones S.L., and McMichael A. Immune responses in HIV-exposed seronegatives: Have they repelled the virus?. Curr. Opin. Immunol. 7 4 (1995) 448-455 Review
122. Rowland-Jones S.L., Dong T., Fowke K.R., Kimani J., Krausa P., Newell H., Blanchard T., Ariyoshi K., Oyugi J., Ngugi E., Bwayo J., MacDonald K.S., et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102 9 (1998) 1758-1765
123. Safrit J.T., Andrews C.A., Zhu T., Ho D.D., and Koup R.A. Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope. J. Exp. Med. 179 2 (1994) 463-472
124. Sakuragi S., Shibata R., Mukai R., Komatsu T., Fukasawa M., Sakai H., Sakuragi J.-I., Kawamura M., Ibuki K., Hayami M., and Adachi A. Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. J. Gen. Virol. 73 Pt 11 (1992) 2983-2987
125. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., and Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science 293 (2001) 1155-1159
126. Scala G., Chen X., Liu W., Telles J.N., Cohen O.J., Vaccarezza M., Igarashi T., and Fauci A.S. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J. Immunol. 162 10 (1999) 6155-6161
127. Scanlan C.N., Pantophlet R., Wormald M.R., Saphire E.O., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., and Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1 ≥ 2 mannose residues on the outer face of gp120. J. Virol. 76 (2002) 7306-7321
128. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., Ghrayeb J., Forman M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 5403 (1999) 857-860
129. Shibata R., Kawamura M., Sakai H., Hayami M., Ishimoto A., and Adachi A. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J. Virol. 65 (1991) 3514-3520
130. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.-Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
131. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., Lockman S., Peter T., Peyerl F.W., Kishko M.G., Jackson S.S., Gorgone D.A., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174 (2005) 7179-7185
132. Ui M., Kuwata T., Igarashi T., Ibuki K., Miyazaki Y., Kozyrev I.L., Enose Y., Shimada T., Uesaka H., Yamamoto H., Miura T., and Hayami M. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs. Virology 265 (1999) 252-263
133. Ui M., Kuwata T., Igarashi T., Miyazaki Y., Tamaru K., Shimada T., Nakamura M., Uesaka H., Yamamoto H., and Hayami M. Protective immunity of gene-deleted SHIVs having an HIV-1 Env against challenge infection with a gene-intact SHIV. J. Med. Primatol. 28 (1999) 242-248
134. Van Baalen C.A., Schutten M., Huisman R.C., Boers P.H., Gruters R.A., and Osterhaus A.D. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J. Virol. 72 8 (1998) 6851-6857
135. Veazey R.S., Shattock R.J., Pope M., Kirijan J.C., Jones J., Hu Q., Ketas T., Marx P.A., Klasse P.J., Burton D.R., and Moore J.P. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9 (2003) 343-346
136. Vuola J.M., Keating S., Webster D.P., Berthoud T., Dunachie S., Gilbert S.C., and Hill A.V. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174 (2005) 449-455
137. Wain-Hobson S., Sonigo P., Danos O., Cole S., and Alizon M. Nucleotide sequence of the AIDS virus, LAV. Cell 40 1 (1985) 9-17
138. Warren J. Preclinical AIDS vaccine research: Survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates. J. Med. Primatol. 31 (2002) 237-256
139. Whatmore A.M., Cook N., Hall G.A., Sharpe S., Rud E.W., and Cranage M.P. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J. Virol. 69 (1995) 5117-5123
140. Willey R.L., Byrum R., Piatak M., Kim Y.B., Cho M.W., Rossio Jr. J.R., Bess Jr. J., Igarashi T., Endo Y., Arthur L.O., Lifson J.D., and Martin M.A. Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. J. Virol. 77 (2003) 1163-1174
141. Wilson J.D., Ogg G.S., Allen R.L., Davis C., Shaunak S., Downie J., Dyer W., Workman C., Sullivan S., McMichael A.J., and Rowland-Jones S.L. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 14 3 (2000) 225-233
142. Wyand M.S., Manson K.H., Garcia-Moll M., Montefiori D., and Desrosiers R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70 (1994) 3724-3733
143. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., and Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73 (1999) 8356-8363
144. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 (1998) 705-711
145. Yewdell J.W., and Del Val M. Immunodominance in TCD8 + responses to viruses: Cell biology, cellular immunology, and mathematical models. Immunity 21 (2004) 149-153
146. Yoshino N., Ami Y., Someya K., Ando S., Shinohara K., Tashiro F., Lu Y., and Honda M. Protective immune responses induced by a non-pathogenic simian/human immunodeficiency virus (SHIV) against a challenge of a pathogenic SHIV in monkeys. Microbiol. Immunol. 44 (2000) 363-372
147. Yu X.G., Addo M.M., Rosenberg E.S., Rodriguez W.R., Lee P.K., et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8 + T-cell responses following acute HIV-1 infection. J. Virol. 76 (2002) 8690-8701
148. Zaunders J.J., Geczy A.F., Dyer W.B., McIntyre L.B., Cooley M.A., Ashton L.J., Raynes-Greenow C.H., Learmont J., Cooper D.A., and Sullivan J.S. Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4 + and CD8 + T lymphocytes: Increased CD45RO + CD4 + T lymphocytes and limited activation of CD8 + T lymphocytes. AIDS Res. Hum. Retroviruses 15 (1999) 1519-1527
149. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 (2007) 732-737
150. Zhu T., Corey L., Hwangbo Y., Lee J.M., Learn G.H., et al. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J. Virol. 77 (2003) 6108-6116
151. Zolla-Pazner S., Lubeck M., Xu S., Burda S., Natuk R.J., Sinangil F., Steimer K., Gallo R.C., Eichberg J.W., Matthews T., and Robert-Guroff M. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72 2 (1998) 1052-1059
152. Zwick M.B., Komori H.K., Stanfield R.L., Church S., Wang M., et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78 (2004) 3155-3161